Enclomiphene vs Clomid: Isomers, Half-Life and Side Effects

The enclomiphene vs Clomid question is unusual because one drug is part of the other. Clomid is clomiphene citrate, a mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). According to the Clomid FDA label, the tablets contain between 30% and 50% of the cis form. The newer drug is simply the trans form, separated out.

The two isomers act differently on estrogen receptors. The 2016 phase III paper by Kim and colleagues describes the trans isomer as an estrogen antagonist, while zuclomiphene "often acts as an agonist". The British Society for Sexual Medicine, in its 2026 statement, calls zuclomiphene more estrogenic and "generally antigonadotropic", and the trans isomer "more anti-oestrogenic" and "pro-gonadotropic". Put simply, one half of Clomid pushes testosterone up and the other half partly works against it.

Both drugs are used for the same purpose in men: raising LH and FSH so the testes make more testosterone while keeping sperm production. The differences lie in how long each stays in the body, how often side effects appear, what they cost, and their legal status. This comparison of enclomiphene vs clomiphene covers each point with the numbers from published studies. For the full background on the newer drug, see our enclomiphene guide.

In the enclomiphene vs Clomid comparison, the biggest pharmacological gap is time. Wiehle and colleagues reported a half-life of about 10.5 hours for enclomiphene and about 30 days for zuclomiphene. The Clomid label adds that in single-dose studies, zuclomiphene was still detectable "for longer than a month".

With daily use, that difference turns into accumulation. A study by Helo and colleagues (BJU International, 2017) measured both isomers in 15 men who had taken Clomid 25 mg daily for a median of about 26 months. The median zuclomiphene level was 44.0 ng/mL against 2.2 ng/mL of enclomiphene, a ratio of about 20 to 1. The drug these men were taking was, in their blood, overwhelmingly the isomer that works against the goal.

The trans isomer alone does not build up in the same way. Its short half-life means levels fall within a day, which is why trials used once-daily dosing. It also means the drug clears quickly after stopping. In the Kaminetsky study (Journal of Sexual Medicine, 2013), testosterone returned to its starting level one month after the last dose.

The accumulation of zuclomiphene is the main reason researchers developed the trans isomer separately. Whether it causes harm over years is not proven, but it offers a plausible explanation for the higher rate of estrogen-type side effects on Clomid.

Only one published study looks at enclomiphene vs Clomid directly in men. Saffati and colleagues (Translational Andrology and Urology, 2024) reviewed 66 men treated with either drug for low testosterone.

Three points stand out. Testosterone rose more on the single isomer but the gap was not statistically significant, so both drugs raise testosterone. Estradiol went in opposite directions, which fits the idea that zuclomiphene adds estrogen-like activity. And side effects were about three times as common on clomiphene.

There are limits. The study was retrospective, not randomized, and small. Men on clomiphene had been treated for longer (median 18.7 months against 8.9 months), which gives more time for side effects to be reported. It is a strong signal, not a final answer. Details of what men experience on each are in enclomiphene side effects and Clomid side effects in men.

On the question of long-term data, Clomid has the stronger record, simply because it has been around longer. It has been used in men since the 1970s, according to a 2019 review by Wheeler and colleagues in Sexual Medicine Reviews.

Several studies followed men on clomiphene for years. Moskovic and colleagues (BJU International, 2012) treated 46 men for more than a year: testosterone rose from 228 ng/dL to 612 ng/dL at 1 year, 562 at 2 years and 582 at 3 years, and no adverse events were reported. Krzastek and colleagues (Journal of Urology, 2019) reviewed 400 men treated for an average of 25.5 months, including 120 treated for more than 3 years. In that group 88% reached normal testosterone, 77% reported better symptoms, and 8% reported side effects, with no significant adverse events.

The trials of the single isomer lasted at most 6 months. There is no multi-year safety data. The European Medicines Agency refused approval in 2018, citing a possible risk of venous thromboembolism and a lack of evidence on symptoms. So the enclomiphene vs Clomid trade-off is clear: the newer drug has cleaner short-term data and fewer side effects in the one comparison available, while clomiphene has a much longer safety record.

The two drugs sit in very different legal positions in the US.

Clomiphene is an FDA-approved, prescription-only drug. Its label covers ovulation induction in women, and doctors prescribe it to men off label, which is legal and backed by many urology studies. The newer drug has no approved product. What is sold is compounded by pharmacies under an FDA interim policy for substances still under evaluation.

Price follows from that. GoodRx listed generic clomiphene from $17.31 at the time of writing, while telehealth enclomiphene plans ranged from $42 per month for certain Hone Health members to $199.99 for a single month at Maximus. Details are in Clomid cost and enclomiphene prescription and cost.

No official guideline settles enclomiphene vs Clomid, so the choice depends on the man and the doctor. Based on the evidence above, the reasoning usually runs along these lines:

Both drugs carry the same class warnings. The Clomid label states that visual disturbances "may be irreversible, especially with increased dosage or duration of therapy", and most doctors apply the same caution to its trans isomer. Both need baseline and follow-up blood work, including estradiol. For how the parent drug works in men, see Clomid for men.

Clomid.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth company or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.